| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 307.9 | 310.6 |
| Gross profit | 137.8 | 134.5 |
| Profit before tax | 15.8 | 9.7 |
| Net income | 11.0 | 5.5 |
| EPS (diluted, $ a share) | $0.24 | $0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +102.2% |
|---|---|
| Revenue, year on year | -0.9% |
| Gross margin | 44.8% |
| Operating margin | 4.9% |
10-Q filed with the SEC, NASDAQ: OMCL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Omnicell, Inc.: key numbers
- Share price
- $35.44Close, Nov 16
- Market cap
- $1.63B
- Shares outstanding
- 46MLatest SEC cover page
- Sector
- Technology
- Industry
- Electronic ComputersSIC 3571
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Omnicell, Inc.
All →Omnicell Financial Results
Omnicell reported third quarter 2026 financial results with revenue of $308 million and GAAP net income of $11 million, both exceeding the high end of previous guidance. The company highlighted strong momentum for its next-generation Titan XT and OmniSphere platforms as healthcare providers prioritize medication management efficiency.
“We delivered solid third quarter results and continued to execute against our strategic priorities. We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management.”
Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell
“At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline. Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability.”
Randall A. Lipps, chairman, chief executive officer, and founder of Omnicell